A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis

This study has been completed.
Sponsor:
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00317330
First received: April 20, 2006
Last updated: August 26, 2010
Last verified: August 2006
  Purpose

This study will test the effectiveness of two different tuberculosis (TB) prevention strategies, DOTS or DOTS-A. DOTS is the current prevention strategy for TB. DOTS-A is an enhanced prevention strategy that will screen household members of individuals diagnosed with active TB and will provide enhanced treatment as needed. The study will be conducted in 8 communities located in Rio de Janeiro. Study participants will include 6400 males and females of all ages, including active TB patients and their household contacts. Patients with TB identified for treatment at the Health Clinics of 8 urban communities will be eligible. The communities will be assigned to 1 of the 2 prevention strategies, DOTS or DOTS-A. After 4 years, the information gathered during the study will be used to determine the incidence of TB in these communities to see which prevention strategy was more effective in decreasing TB.


Condition Intervention Phase
Tuberculosis
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Rifampin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment: 6400
Study Start Date: December 2004
Estimated Study Completion Date: June 2005
Detailed Description:

This will be a single site, prospective, community-randomized trial to study the effectiveness for two TB prevention strategies on the community incidence of TB: DOTS versus Enhanced DOTS (DOTS-Ampliado, or DOTS-A). DOTS-A will add intensive screening of household contacts of active TB cases and the provision of TB treatment or prophylaxis as needed to the standard DOTS regimen. Adult contacts in the DOTS-A communities will be offered enrollment into a randomized clinical trial comparing rifapentine/isoniazid preventive therapy to rifampin/pyrazinamide. Subjects will be recruited from TB cases identified for treatment at the Health Clinics of eight urban communities. These communities will be matched and randomly assigned to receive either DOTS or DOTS-A strategy. The change in the incidence of TB in the two groups of communities will be measured after a 4-year period to determine whether DOTS-A strategy significantly reduces the incidence of TB compared to DOTS alone.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Cases will include:

  1. Any age male or female with new or recurrent diagnosis of TB
  2. Willingness and ability to adhere to study medications and protocol procedures.
  3. Willingness to provide signed informed consent or signed informed consent/assent provided by parent or legal guardian.

Contacts will include:

  1. Male or female living in household of a pulmonary TB case, at high risk for developing TB (but without evidence for active TB).
  2. High-risk household contacts will be defined as those who are:

    • HIV seropositive, regardless of the results of initial tuberculin skin test (TST)
    • TST positive at the time of the first household evaluation. TST positivity will be defined as greater than or equal to 5 mm induration of 5 TU of PPD using the Mantoux method, read between 48 and 72 hours after application.
    • TST negative at the time for the first household evaluation and TST positive at the time of the second household evaluation 3 months later.
    • Willingness to provide signed informed consent or signed informed consent/assent provided by parent or legal guardian.

Exclusion Criteria:

Contacts will be excluded from preventive therapy if:

  1. Current active clinical tuberculosis-confirmed or suspected
  2. History of sensitivity/intolerance to any of the study medications
  3. Evidence of acute hepatitis
  4. History or laboratory evidence of cirrhosis
  5. Pregnant females (treatment of latent infection will be deferred)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00317330

Locations
Brazil
Municipal Health Department
Rio de Janeiro, Brazil, 21945
Sponsors and Collaborators
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00317330     History of Changes
Other Study ID Numbers: 01-581, ICIDR#1
Study First Received: April 20, 2006
Last Updated: August 26, 2010
Health Authority: Unspecified

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Isoniazid
Pyrazinamide
Rifampin
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Fatty Acid Synthesis Inhibitors
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Antibiotics, Antitubercular
Enzyme Inhibitors
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on August 26, 2014